---
document_datetime: 2026-02-24 09:45:30
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zoledronic-acid-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zoledronic-acid-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.2979235
conversion_datetime: 2026-02-25 11:44:52.432881
docling_version:
  docling-serve: 1.13.1
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.2
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.4
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Zoledronic Acid Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / | This was an application for a group of | 23/02/2026                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000333357   | variations. Q.II.b.2.c) Addition or replacement of a site responsible for batch release (QP certification) - Q.II.b.2.c.2 Including batch control/testing applying physicochemical and/or microbiological analytical procedures for the finished product - Accepted Q.II.b.1 Change in the manufacturing site for part or all of the manufacturing process of the finished product (except for batch release and batch control testing sites) - Q.II.b.1.a) Addition or replacement of a site responsible for secondary packaging - Accepted   |            | PL   |                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|-------------------|
| Variation type IA / | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.c) Container closure system - B.I.c.z Change of a secondary packaging component of the drug substance (including replacement or addition) - Accepted                 | 22/01/2026 |      | EMA/VR/0000323445 |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000316678   | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted   | 11/12/2025   |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Variation type IB / EMA/VR/0000287084   | This was an application for a group of variations. B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the                                                                             | 14/10/2025   |

<div style=\"page-break-after: always\"></div>

| originally approved batch size - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.e Minor change to the restricted part of an Active Substance Master File - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.z Other changes - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| used in the manufacture of the active             |
|---------------------------------------------------|
| substance (where specified in the technical       |
| dossier) where no Ph. Eur. Certificate of         |
| Suitability is part of the approved dossier; or   |
| a manufacturer of a novel excipient (where        |
| specified in the technical dossier) - Accepted    |
| B.I.a.1 Change in the manufacturer of a           |
| starting material/reagent/intermediate used       |
| in the manufacturing process of the active        |
| substance or change in the manufacturer           |
| (including where relevant quality control         |
| testing sites) of the active substance, where     |
| no Ph. Eur. Certificate of Suitability is part of |
| the approved dossier - B.I.a.1.f Changes to       |
| quality control testing arrangements for the      |
| active substance-replacement or addition of       |
| a site where batch control/testing takes          |
| place - Accepted                                  |
| B.I.a.1 Change in the manufacturer of a           |
| starting material/reagent/intermediate used       |
| in the manufacturing process of the active        |
| substance or change in the manufacturer           |
| (including where relevant quality control         |
| testing sites) of the active substance, where     |
| no Ph. Eur. Certificate of Suitability is part of |
| the approved dossier - B.I.a.1.f Changes to       |
| quality control testing arrangements for the      |
| active substance-replacement or addition of       |
| a site where batch control/testing takes          |
| place - Accepted                                  |

<div style=\"page-break-after: always\"></div>

| Article 61(3) / EMA/N/0000267263      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet to introduce a list of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 02/05/2025   | PL          |                                                                                                                                                                                                                                                                                                                                          |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000226953 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted To align the RMP for Zoledronic Acid Accord with the RMP of the reference product. In addition for the nationally authorised products Zoledronic Acid Accord 4 mg/5 ml, 4 mg/100 ml concentrate for solution for infusion (product reference PT/H/0742/001/DC) the RMP is being merged with the RMP of the centrally authorised product. | 13/03/2025   |             | To align the RMP for Zoledronic Acid Accord with the RMP of the reference product. In addition for the nationally authorised products Zoledronic Acid Accord 4 mg/5 ml, 4 mg/100 ml concentrate for solution for infusion (product reference PT/H/0742/001/DC) the RMP is being merged with the RMP of the centrally authorised product. |
| Variation type IB / EMA/VR/0000231938 | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 13/11/2024   | SmPC and PL |                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                                          | the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.z Other variation - Accepted Update of section 4.8 of the SmPC to add the adverse reaction \"Tubulointerstitial nephritis\" with the frequency \"not known\", following the assessment and approval of the same changes in the reference product. The Package leaflet has been updated accordingly.   |            |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type IA_IN / EMA/VR/0000228564 | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.a Implementation of wording agreed by the competent authority - Refused           | 30/09/2024 |